Chart: "JMFF's Winners"
This article was originally published in Pharmaceutical Approvals Monthly
Among the recipients of Michael J. Fox Foundation grants, ShanRx, in Woodside, Calif., is identifying neuroprotective drugs that work in the P13K signaling pathway. With the MJFF funding, the start-up aims to identify candidates and establish safety and efficacy in a rat model. Recently public Omeros, in Seattle, will get up to $465,000 from the foundation to further investigate a novel target (cyclic nucleotide phosphodiesterase type 7, implicated in movement disorders) it identified under an earlier MJFF deal. Another winner, California drug discovery and diagnostics play KineMed, is working on a way of showing that cerebrospinal fluid-based biomarkers can be used to track the progress of Parkinson's disease and possibly to discover new points of therapeutic intervention by shedding light on the pathogenesis of the disease.
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class